Pfizer Inc. - PFE STOCK NEWS

Pfizer (NYSE: PFE) has partnered with UNICEF to provide up to 4 million treatment courses of its COVID-19 oral medication, PAXLOVID™, to 95 low- and middle-income countries starting in April 2022. This initiative aims to enhance global access to COVID-19 treatment, with the courses being offered at a not-for-profit price for lower-income countries. Pfizer anticipates producing up to 120 million treatment courses by the end of 2022, depending on global demand. The agreement aligns with Pfizer's commitment to equitable access amidst the ongoing pandemic.

IDEAYA Biosciences (IDYA) has collaborated with Pfizer (PFE) to enhance clinical trials evaluating the combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM) and cMET-driven tumors. The Phase 2 trial could enable registration, with promising preliminary data showing robust activity. IDEAYA plans to provide an update on clinical data in mid-2022 and will seek FDA guidance for trial design. This partnership aims to elevate treatment standards for patients with high unmet needs and potentially expand to other cancer types.

Pfizer Inc. (NYSE: PFE) has successfully completed the acquisition of Arena Pharmaceuticals for $100 per share, totaling approximately $6.7 billion. This strategic move aims to enhance Pfizer's capabilities in treating immuno-inflammatory diseases, leveraging Arena's promising pipeline, including etrasimod. Etrasimod is being developed for conditions such as ulcerative colitis and Crohn's Disease. The acquisition is anticipated to advance Pfizer’s Inflammation and Immunology therapeutic area.

Pfizer has commenced the Phase 2/3 EPIC-PEDS study to assess the safety and efficacy of PAXLOVID™ in children with COVID-19. This follows promising data from the EPIC-HR study, showing an 89% reduction in hospitalization or death risk in high-risk adults. The pediatric study aims to enroll around 140 participants under 18, focusing on those weighing at least 20 kg. PAXLOVID is already authorized in over 50 countries, with more than 1.5 million courses delivered and expectations of 30 million by July. The company remains committed to equitable access through tiered pricing and increased production capabilities.

Pfizer Inc. (NYSE: PFE) will host a webcast featuring its Inflammation & Immunology leadership team at the Barclays Global Healthcare Conference on March 15, 2022, at 10:45 a.m. EDT. Key speakers include Michael Gladstone, Michael Vincent, and Michael Corbo. Investors and the public can access the live discussion and subsequent replay on Pfizer's investor website. The discussion aims to cover key insights into Pfizer's strategies and product pipeline. A transcript will also be available within 24 hours, remaining accessible for 90 days.

Pfizer Inc. (NYSE:PFE) announced that its RSV vaccine candidate, RSVpreF, received Breakthrough Therapy Designation from the FDA for preventing RSV-associated respiratory illness in infants via maternal immunization. The designation is based on Phase 2b study results, focusing on safety and immunogenicity. Pfizer anticipates future publications regarding the trial outcomes. Approximately 2.1 million outpatient visits occur annually in the U.S. due to RSV in young children, highlighting the significance of this potential vaccine.

Pfizer announced findings from the CLOVER trial, a Phase 3 study evaluating its C. difficile vaccine candidate (PF-06425090). Although the trial did not meet its primary endpoint, it showed promising results in secondary endpoints, indicating 100% efficacy in preventing medically attended infections and a significant reduction in disease duration. The vaccine was well tolerated with a favorable safety profile. Pfizer is assessing the next steps for the vaccine program in coordination with regulatory agencies.

Pfizer Inc. (NYSE: PFE) will host a webcast featuring its executives, Angela Hwang, Andy Schmeltz, and Suneet Varma, at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:50 a.m. EST. Investors and the public can access the live discussion through www.pfizer.com/investors. A transcript and replay will be available within 24 hours for 90 days. Pfizer focuses on delivering therapies that significantly improve patients’ lives and routinely provides important updates on its website.

Biohaven and Pfizer have received a positive opinion from the CHMP for rimegepant, a new treatment for migraines, recommending its 75 mg dose for both acute and preventive use in adults. This marks a significant advancement, as rimegepant is set to become the first oral CGRP receptor antagonist in the EU under the trade name VYDURA™, pending European Commission approval. The CHMP's recommendation was based on results from multiple Phase 3 studies that demonstrated rimegepant's safety and efficacy in treating migraines, addressing a crucial unmet need for patients.